An investigation on behalf of investors in NASDAQ:ZSPH shares was announced concerning whether the takeover of ZS Pharma Inc. by AstraZeneca is unfair.
Investors who purchased shares of ZS Pharma Inc (NASDAQ:ZSPH) and currently hold any of those NASDAQ:ZSPH shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain officers and directors of ZS Pharma Inc breached their fiduciary duties owed to NASDAQ:ZSPH investors in connection with the proposed acquisition.
On November 6, 2015, AstraZeneca announced hat it has entered into an agreement to acquire ZS Pharma Inc (NASDAQ:ZSPH). Under the terms of the agreement, AstraZeneca will acquire all of the outstanding capital stock of ZS Pharma for $90 per share in an all-cash transaction, or approximately $2.7 billion in aggregate transaction value.
However, the investigation concerns whether the offer is unfair to NASDAQ:ZSPH stockholders. More specifically, the investigation concerns whether the ZS Pharma Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders’ best interests in connection with the proposed sale.
On December 4, 2015, ZS Pharma Inc shares closed at $89.69 per share.
Those who are current investors in ZS Pharma shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego